NCT05934097 - FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | Biotech Hunter

Timeline

Start Date

December 31, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2039

Conditions

Diffuse Large B Cell LymphomaTransformed Indolent Non-Hodgkin's LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone Lymphoma

Interventions

DRUG

FT596

Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously

DRUG

Cyclophosphamide

750 mg/m\^2 intravenously

DRUG

Doxorubicin

50 mg/m\^2 intravenously

DRUG

Vincristine

1.4 mg/m\^2 (maximum dose 2 mg) intravenously

DRUG

Prednisone

100 mg orally

DRUG

Rituximab

375 mg/m\^2 intravenously

DRUG

Bendamustine

90 mg/m\^2 IV infusion